Company ProfilePremium

Pharmasimple SA

Company Profile Analysis

Ticker: ALPHS.PA

ESOMAR 23 Corporate BadgeISO Certifications Badge
Pharmasimple SA - Company showcase

Year Founded & Workforce

2010

10 Employees

Pharmasimple SA logo

Pharmasimple SA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Pharmasimple SA Overview

Pharmasimple was a Belgian online parapharmacy that, between 2010 and 2021, built one of the larger French-language e-commerce businesses for dermo-cosmetics, hygiene, food supplements and other non-prescription health and beauty goods, selling overwhelmingly into France from a logistics base in Wallonia. A roll-up of two French platforms — Parapharmazen (2018) and Enova Santé's 1001Pharmacies.com (2019) — and the COVID-19 demand spike lifted revenue to a record EUR 45.2M in 2020, but the business remained structurally low-margin and cash-hungry. After demand normalised in 2021, management abandoned the pure-play model in favour of acquiring brick-and-mortar Belgian pharmacies, financed largely by convertible instruments and loans from Alpha Blue Ocean's Global Tech Opportunities 12 fund. The pivot failed: the online platforms were sold in late 2022, the pharmacy network shrank, financing was withdrawn in May 2023, and the company was declared bankrupt in June 2023. It is now a shell in liquidation.


Company's own description (latest available)

The company's final boilerplate (January–May 2023 press releases) described Pharmasimple as a distribution group specialising in the sale of pharmaceutical and parapharmaceutical products, operating a network of pharmacies in Belgium (described as "about fifteen" in January 2023 and "about ten" in May 2023), with the ambition of becoming one of the leaders of its sector in Belgium through an aggressive external-growth programme. Pharmasimple never published a full-length annual report in English or a risk-factor-style business section; the only formal descriptive document located is the FSMA-filed information note of 18 November 2019, which describes the issuer as the owner of the pharmasimple.com website since its incorporation.

Earlier boilerplate (2017–2022) described the company as a specialist in online parapharmacy, "one of the main players in France", offering more than 120,000 product references in cosmetics, dermo-cosmetics, medical accessories and food supplements, holding Bpifrance's "Entreprise innovante" label, and aiming to become a European sector leader.

Independent characterisation

PhasePeriodModelRevenue modelValue-chain position
1. Online pharmacy start-up2010–2013Website initially selling general pharmacy medicinesProduct resale (retail margin)Online retailer
2. Online parapharmacy pure-play and roll-up2013–2021Refocused on parapharmacy (non-medicine health & beauty) because medicine margins were poor; acquired Parapharmazen and 1001Pharmacies; some B2B product sales~100% product resale; 1001Pharmacies brought a marketplace (commission) dimension; no subscription or licensing revenue disclosedDownstream online retailer/marketplace buying from laboratories/wholesalers and shipping to consumers, primarily in France
3. Omnichannel / pharmacy networkDec 2021–May 2023Acquisition of Belgian community pharmacies (mostly rural), concept store and in-store kiosks, real-estate sub-holding for pharmacy premises; online platforms divested in late 2022Product resale in pharmacies (OTC, prescription dispensing, parapharmacy)Brick-and-mortar retail pharmacy operator

Across its life Pharmasimple ran three successive business models:

Customer types and end-markets. B2C consumers in France (about 90% of sales in 2017, per Euronext's listing profile) and Belgium/Benelux; a minor B2B product channel was referenced in 2020. At its 2016–2017 listing, the company claimed more than 300,000 customers and roughly 120,000 orders a year across 770 brands. End-markets: French and Belgian parapharmacy (dermo-cosmetics, hygiene, mother & baby, supplements, veterinary), then Belgian community pharmacy.

Economic character. Pharmasimple was a price-led, search-traffic-dependent reseller with thin gross margins (14.5% of sales in H1 2020, 10.8% in H1 2021, per half-year releases) and high marketing and logistics costs. The model only produced positive EBITDA in the single COVID-boosted year of 2020 (EBITDA EUR 1.0M on EUR 45.2M sales). Gross margin improved to about 20% in H1 2022 as pharmacies were consolidated, but restructuring costs and stock write-downs overwhelmed it.

Strategy

Stated strategy themes (in the company's own framing, paraphrased)

  • 2016–2019 — "Build-up" leadership in French online parapharmacy: grow organic SEO traffic, develop own brands, and consolidate the fragmented online market through acquisitions; ambition to be a European leader.

2019 — "Pharmasimple 2023" plan: referenced in the February 2020 release as a plan to be presented with the FY2019 results; return to operating breakeven targeted in 2020. The plan's detailed targets were not captured in the sources reviewed.

December 2021 — Complete business-model overhaul: shift to an online/offline mix to cut marketing spend, reduce dependence on paid traffic, and add recurring revenue and advice-driven margin through pharmacies; concept store with kiosks.

2022 — Pharmacy network: acquire at least 15 pharmacies in 2022 and build a group of 150–200 pharmacies within five years; combine Pharmasimple's procurement and logistics expertise with local pharmacist advice; real-estate sub-holding for pharmacy premises; the CEO framed this as turning the stock into a more defensive investment.

2023 — Restructure, deleverage, then resume acquisitions: cut staff, dispose of non-core activities, clear liabilities, restart pharmacy acquisitions once total debt was back near EUR 1M.

Initiatives announced in the final 24 months before bankruptcy (May 2021 – May 2023)

DateInitiativeTarget / metricOutcome
Aug 2021EUR 10M OCABSA programme with GTO 12Fund working capital and growth without immediate large dilutionDrawn in tranches; ended with funding withdrawal in May 2023
2,021Concept store and kiosksReach traditional customers with online functionalityNo metrics disclosed
Dec 2021Strategic overhaulOnline/offline mix from 2022Executed, then failed
Mar 2022Bank debt clearedZero bank debt by end of Q1 2022Achieved per company
Mar 2022First 5 pharmacies~EUR 7M annual revenue; ~EUR 0.7M EBITDA contributionIntegrated May 2022
May 2022Pharmacies 8–127 pharmacies to deliver EUR 8.7M first full-year revenue; 4 more ~EUR 5MPartly integrated; 4 deferred to mid-2023
Jul 2022Pharmasimple ImmoHold pharmacy premises—
Oct 2022Confirmation of ≥15 pharmacies in 2022—14 reported by July 2022; about 15 by Jan 2023
Dec 2022Reverse splitClean up share register; holders under 50,000 old shares cashed outExecuted 12 Dec 2022
Dec 2022–Jan 2023Sale of Pharmasimple.com and Parapharmazen.comExit loss-making online activitiesCompleted; buyer and price not publicly disclosed
Jan 2023EUR 5.64M GTO 12 loanFinish restructuring, honour short/medium-term obligationsFunding stopped in May 2023
Jan 20232023 guidance~EUR 6M revenue; operating profitability for continuing (pharmacy) operationsNot achieved — bankruptcy

ESG commitments, cost-programme savings targets and medium-term margin targets: not publicly disclosed.

Products & Services

Pharmasimple was a reseller; it did not manufacture. Product detail below is drawn from company boilerplate, listing documents, aggregator business descriptions and press releases.

E-commerce platforms (Online segment, 2010–2022)

PlatformDescriptionTarget customerLaunch / acquisitionPricing modelFate
Pharmasimple.comFlagship online parapharmacy; 120,000 references across ~770 brands (2017). Organic search traffic to the site rose 167% in H1 2020French and Benelux consumersLaunched 2010Discount retail pricing; "PharmaDeals" offers and "My Pharmasimple" loyalty discounts are referenced in current third-party profilesSold, finalised by Jan 2023 (buyer not publicly disclosed)
Parapharmazen.comGeneralist French online parapharmacy, described as the 4th-largest French siteFrench consumersAcquired Apr 2018RetailSold, finalised by Jan 2023
1001Pharmacies.com (Enova Santé)Marketplace connecting consumers and sellers; ~90% of its traffic from SEO at acquisition. A 2014–2016 French court case had already barred it from selling medicines online (CNOP v. Enova Santé), confining it to parapharmacyFrench consumersAcquired Jan 2019; consolidated Apr 2019Marketplace / retailFate pending in Q1 2023; outcome not publicly disclosed

Product categories sold online (as described by data providers and the company)

CategoryExamplesNotes
Beauty & dermo-cosmeticsFace cleansing and care, make-up, hair removal, body care, tanning, hair treatments, perfumeCore traffic driver; brands referenced on profiles include Clinique among others
HealthFeminine hygiene, dental hygiene, alternative medicine, hearing aids, aromatherapyNon-prescription
Men's careFace, body, hair care; shaving—
Diet & nutritionDiet products, sports nutrition, supplements, health food, meal replacementsHigh-recurrence category emphasised in 2016
Mother & babyNappies, baby washing, breastfeeding equipment, baby food, baby care—
Veterinary & pest controlPet health products—
Medical accessoriesListed in boilerplate—
Own brandsIn 2016 the company said it intended to develop its own innovative product brandsNo own-brand launch was ever disclosed

Offline / omnichannel offerings (2021–2023)

OfferingDescriptionLaunchStatus
Pharmasimple Concept StorePhysical store with interactive kiosks bringing internet functionality to traditional customers2,021Not publicly disclosed after 2022
Pharmasimple-affiliated pharmaciesAcquired community pharmacies rebranded with Pharmasimple signage and plugged into group purchasing; personalised advice, OTC and prescription dispensing, parapharmacyFrom Mar 2022In liquidation
PharmaDeals / My Pharmasimple loyaltyExclusive offers and loyalty discounts (referenced on current third-party profiles)——

Pricing schedules, unit economics per channel and average basket were never disclosed.

Financial Narrative

Basis of preparation. Figures come from company press releases (consolidated, some unaudited), Belgian statutory accounts as summarised by registry aggregator Signumi (FY2021, likely non-consolidated), and — for net margins FY2017–FY2020 — an aggregator (Rendementbourse) whose figures could not be reconciled with primary documents and are flagged accordingly. No audited FY2022 or FY2023 accounts were published. Blank cells = not publicly disclosed.

Income statement

Sources: FY2017–FY2018 revenue, results release 26 Apr 2019; FY2019 revenue, release 5 Feb 2020; FY2019–FY2020 EBITDA and FY2020 revenue, results release 14 Apr 2021; FY2021 revenue, release 23 Feb 2022 (company: EUR 30.0M; statutory accounts: EUR 29.9M); FY2021 EBITDA (EUR –4.59M) and net loss (EUR –8.94M), Belgian statutory accounts via Signumi; FY2017–FY2020 net margin, Rendementbourse; FY2021 net margin computed. The FY2020 results release states the net loss was significantly reduced versus FY2019, consistent with the aggregator's direction. No dividend was ever paid.

Revenue CAGR: FY2017–FY2021 = 12.1% p.a. (EUR 19.0M → EUR 30.0M); FY2018–FY2020 = 64.0% p.a. (acquisitions + COVID); FY2015–FY2020 = 46.0% p.a. (EUR 6.8M → EUR 45.2M). Computed from the figures above.

Half-year detail (the most granular disclosure available)

Sources: releases of 21 Jul 2020, 25 Feb 2021, 28 Jul 2021, 7 Oct 2021, 23 Feb 2022, 11 Oct 2022; Cercle Finance 8 Oct 2021; Signumi (FY2021 cash). Discrepancies: H1 2021 revenue is shown as EUR 15.9M (Jul 2021 release) and EUR 16.0M (Oct 2021 results); end-2020 net debt is EUR 5.2M (FY2020 results) versus EUR 5.3M (H1 2021 results comparator). H1 2022 revenue is EUR 13.6M in the October results versus EUR 14.7M in the July revenue release.

Balance sheet

Sources: FY2020 results release (equity EUR 5.5M; accounting net debt EUR 5.2M including a EUR 3.9M bond issued for the 1001Pharmacies acquisition); FY2021 statutory accounts via Signumi (total assets EUR 18.19M, debt EUR 14.00M, cash EUR 1.12M, equity EUR 4.14M); company restructuring updates of 9 Feb, 7 Mar and 11 Apr 2023 (net debt and payables at 31 Dec 2021, 31 Dec 2022, 28 Feb and 31 Mar 2023; equity EUR 4.1M → 3.8M → 2.0M → 1.9M). The short/long-term split of debt was not publicly disclosed. Non-current liabilities rose by EUR 3.9M in H1 2019 because of the 1001Pharmacies acquisition financing (H1 2019 results, 18 Oct 2019).

Cash flow

Sources: FSMA decision (EUR 5M capital increase closed 4 Dec 2019); release 27 Aug 2019 (EUR 0.5M loans); releases 30 Aug 2021 and 27 Jan 2023. Cash-flow statements were never published in press releases. A short-term credit line top-up of EUR 1.7M by end of May 2022 was also referenced (release 3 Mar 2022).

Ratios (computed where inputs exist)

Sources: FY2021 liquidity, solvency and gearing ratios from Signumi; ROE, ROA, asset turnover, revenue per FTE and FY2020 net debt/EBITDA computed from figures in 6.1–6.3. FY2021 net debt/EBITDA is not meaningful (negative EBITDA).

Commentary on trends, inflections and drivers

2017–2018: contract loss masks underlying growth. Revenue fell from EUR 19.0M to EUR 16.8M in 2018 because a distribution contract with a large European laboratory signed in 2017 was not renewed; excluding it, management claimed 22% pro forma growth, driven by rising natural (SEO) traffic. The year was loss-making (H1 2018 net loss EUR 1.1M) as the company invested in its website and a new logistics building and absorbed Parapharmazen.

2019: acquisition-led scale, chronic liquidity strain. Revenue jumped 67% to EUR 28.1M (around 40% excluding the 1001Pharmacies contribution, per the February 2020 release), but EBITDA stayed negative (EUR –1.3M). The FSMA's 2025 decision provides an unusually candid view of the period: early 2019 combined rising sales with heavy losses, growing cash needs, large supplier arrears and strained supplier relations; every external investor approached in spring 2019 declined. The company survived on EUR 0.5M of shareholder bridge loans and a deeply discounted EUR 5M rights-style capital increase in which the founder's group took 71% of the new shares.

2020: the COVID peak. Lockdowns pushed H1 2020 revenue up 111% to EUR 30.2M; full-year sales reached EUR 45.2M and EBITDA turned positive at EUR 1.0M — the only positive EBITDA year in the company's listed history. Fixed costs rose only EUR 0.7M (+23%) as volume absorbed overhead. Even so, EBITDA margin was just 2.2%, revealing how little operating leverage the model had.

2021: reversal and cash burn. With demand normalising, H1 2021 sales fell 47%, gross margin compressed from 14.5% to 10.8% as the company leaned on paid search (SEA) to defend volumes, and net debt rose to EUR 7.4M by June. Full-year statutory accounts show EBITDA of EUR –4.6M and a net loss of EUR –8.9M — the net loss was nearly 30% of revenue. Equity of EUR 4.1M against EUR 14.0M of debt left a solvency ratio of 22.8%. The September 2021 convertible facility with GTO 12 was the lifeline.

2022: the pivot that destroyed the remaining value. The company used convertible-bond proceeds to clear bank debt and buy pharmacies. Gross margin improved to roughly 20% in H1 2022, but online revenue fell to EUR 10.8M (–32%), EBITDA worsened to EUR –3.6M (including large reorganisation costs), and stock write-downs pushed the half-year operating loss to EUR –6.0M. By year-end the online platforms were sold, more than 50 of 65 employees had left, and equity was EUR 3.8M.

2023: collapse. Equity halved again to EUR 1.9M by March 2023 as some pharmacy acquisitions were unwound. Management projected about EUR 6M of 2023 revenue from the remaining pharmacies. When GTO 12 stopped funding in early May 2023, the company declared itself insolvent within days.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryRoleStatus

Pharmasimple SA

Belgium

Listed parent; operated pharmasimple.com until late 2022; owner of pharmacy businesses

Bankrupt (Jun 2023)

Parapharmazen (platform/company)

France

Online parapharmacy (4th-largest French site at acquisition, per FSMA)

Platform sold late 2022 (buyer not publicly disclosed)

Enova Santé SAS

France (Lunel/Montpellier area)

Publisher of marketplace 1001Pharmacies.com

Fate "to be determined" in Q1 2023; outcome not publicly disclosed

Pharmasimple Immo

Belgium

Real-estate sub-holding to hold pharmacy premises (created Jul 2022)

Status not publicly disclosed

Second new entity (Jul 2022)

Belgium

Created alongside Pharmasimple Immo to reflect pharmacy strategy; name not captured in sources reviewed

—

Acquired pharmacies (up to 14 by Jul 2022)

Belgium (mostly rural)

Community pharmacies affiliated to the Pharmasimple banner

Several "retroceded" in early 2023; remainder fell into bankruptcy

“—” = not publicly disclosed.

Revenue by Segment and Revenue by Segment (%)

Segment (EUR Mn)H1 2021H1 2022

E-commerce revenue

15.910.8

Pharmacies (offline) revenue

03.9

Total revenue (July 2022 revenue release)

15.914.7

E-commerce share of total (%)

10073.5

Pharmacies share of total (%)

026.5

E-commerce YoY growth (%)

—-32.1

Revenue by Segment

Segment (EUR Mn)FY2019FY2020FY2021

Online / e-commerce (incl. minor B2B)

28.145.230.0

Pharmacies

000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2017FY2018FY2019FY2020FY2021FY2022

Revenue (EUR Mn)

19.016.828.145.230.0—

Revenue growth YoY (%)

—-11.667.360.8-33.6—

EBITDA (EUR Mn)

——-1.31.0-4.6—

EBITDA margin (%)

——-4.62.2-15.3—

Net income (EUR Mn)

————-8.9—

Net margin, aggregator (%)

-7.15-14.25-11.07-3.27-29.9—

Dividends per share (EUR)

000000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (Half-Yearly)

MetricH1 2020H2 2020H1 2021H2 2021H1 2022

Revenue (EUR Mn)

30.215.115.914.113.6

Gross margin (% of revenue)

14.5—10.8—20.0

Gross profit (EUR Mn)

————2.7

EBITDA (EUR Mn)

1.4—-1.7—-3.6

Operating income (EUR Mn)

0.3—-2.9—-6.0

Net income (EUR Mn)

0.3—-3.0——

Net debt, end of period (EUR Mn)

—5.27.48.63.5

Cash, end of period (EUR Mn)

———1.13.6

Balance Sheet

MetricFY2020FY2021FY2022Mar 2023

Total assets (EUR Mn)

—18.2——

Cash & equivalents (EUR Mn)

—1.1——

Total debt (EUR Mn)

—14.0——

Net debt (EUR Mn)

5.28.60.81.0

Trade payables (EUR Mn)

—3.62.82.0

Shareholders' equity (EUR Mn)

5.54.13.81.9

Balance Sheet (FY2019–FY2022)

MetricFY2019FY2020FY2021FY2022

Dividends paid (EUR Mn)

0000

Share buybacks (EUR Mn)

0000

Equity raised (EUR Mn)

5.0———

Shareholder bridge loans (EUR Mn)

0.5———

Convertible programme signed (EUR Mn)

——10.0—

Loan signed (EUR Mn, Jan 2023)

———5.6

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2020FY2021

ROE (%)

—-216

ROA (%)

—-49

Current ratio (x)

—1.1

Quick ratio (x)

—0.8

Debt / equity (x)

—3.4

Solvency ratio, equity / assets (%)

—22.8

Net debt / EBITDA (x)

5.2—

Asset turnover (x)

—1.64

Revenue per FTE (EUR Mn)

—0.52

Region (% of Revenue) Overview

Region (% of revenue)FY2017

France (% of revenue)

90

Belgium & other (% of revenue)

10

Share Price History

DatePrice (EUR)EventSource

Nov 2016

7.50

Direct listing price

Release 20 Mar 2017

15 Mar 2017

13.85

+85% from listing

Release 20 Mar 2017

Jan–Oct 2021

—

Stock down about 76% YTD by 8 Oct 2021

Cercle Finance

15 Mar 2023

0.275

Post-consolidation line, +82% intraday

Zonebourse

16 May 2023

0.013

Last price at suspension

BFM Bourse

2023 calendar year

—

–99.72%

Zonebourse

Valuation Snapshot

MetricValue

1-year share price performance

Not meaningful — suspended since 16 May 2023

3-year share price performance

Not meaningful (effectively –100%)

5-year share price performance

Not meaningful (effectively –100%)

P/E

Not meaningful (losses; bankrupt)

Analyst consensus

No sell-side coverage identified

Dividend history

No dividends ever paid

Buyback authorisations

None disclosed

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

Not publicly disclosed; all claims now subject to bankruptcy ranking

Formal delisting date

Not located in public sources; vendors show the instrument as inactive / no longer quoted

Instrument by Date

DateInstrumentAmount (EUR Mn)Counterparty

Oct 2016

Private placement

1.0

News Invest, Sopromec

Sep 2017

Placement with transfer to Euronext Growth

—

Four small-cap funds and others

Jan 2019

Shares + convertible bonds (acquisition consideration)

3.9 (bond portion)

Enova Santé shareholders

Dec 2019

Capital increase

5.0

Existing shareholders; Willems group 2.32

Aug 2021

OCABSA programme

10.0 (maximum)

GTO 12

Jan 2023

Loan

5.64

GTO 12

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance. The last guidance (3 January 2023) called for roughly EUR 6M of 2023 revenue from pharmacies and operating profitability on continuing operations, with acquisitions to resume once total debt returned to about EUR 1M. This guidance lapsed with the bankruptcy. There is no consensus estimate and none will be produced.

Bull-case arguments (now essentially academic)

  1. Creditor recoveries from asset sales. The estate may realise value from remaining pharmacy licences/goodwill and any real estate held via Pharmasimple Immo; Belgian pharmacy licences have historically commanded meaningful prices.

  2. Litigation or recovery actions. Trustees could pursue claims (against directors or counterparties) that augment the estate, given the FSMA's findings on 2018–2019 conduct.

  3. The franchise once had real traction. A business that reached EUR 45.2M of sales and 23.5M annual visits demonstrated consumer demand; the brands sold in 2022 may survive under new owners — but that value accrues to buyers, not to Pharmasimple shareholders.

Bear-case arguments (decisive)

  1. Equity is worthless. With a single creditor claiming EUR 29.8M against last reported equity of EUR 1.9M, shareholders rank behind creditors in a liquidation and should expect zero recovery.

  2. The disclosed financials are unreliable. The gap between reported net debt (EUR 0.8–1.0M) and the EUR 29.8M claim undermines any valuation built on company figures.

  3. The model never generated sustainable profit. Only one positive EBITDA year (2020, 2.2% margin) in the listed history, and the online assets — the only scaled business — were sold.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Trustees' reports and claims verification in the Charleroi courtDetermines creditor recoveries and the treatment of the GTO 12 claim
Any formal Euronext delisting noticeClarifies the security's legal status for holders (tax loss crystallisation)
Criminal complaint outcomePotential director-liability findings
Expiry of FSMA named publication (Dec 2026)Procedural closure of the regulatory case
Any director-liability or clawback action by trusteesOnly realistic source of additional estate value

Analyst verdict

Pharmasimple is no longer an investable company; it is a bankruptcy estate. The dossier above should be read as a post-mortem.

The core lesson is that revenue growth in online parapharmacy was never matched by unit economics. Across 2017–2021 the company more than doubled its peak revenue through two French acquisitions and a pandemic windfall, yet produced positive EBITDA only once, at a margin of about 2%. Gross margins of 10–15% left no room for the marketing spend required to hold search-driven traffic once COVID demand faded, and the 2021 collapse — a net loss near 30% of sales — exhausted the balance sheet.

The response compounded the problem. Rather than shrink to a defensible niche, management pivoted to a capital-intensive pharmacy roll-up targeting 150–200 outlets, funded almost entirely by convertible bonds and loans from a single alternative financier. That structure made the company's survival contingent on one counterparty's continued willingness to fund. When Global Tech Opportunities 12 stopped in May 2023, insolvency followed within days, and the creditor's EUR 29.8M claim exposed how little the company's own "net debt" disclosures had told investors.

Governance failures run through the story. The FSMA's December 2025 decision found that the founder-CEO traded on inside information, supported the share price with offsetting orders and misled forum investors during the 2019 liquidity crisis, while failing to declare more than 1,700 transactions. The modest fines reflect the age of the facts and the founder's own losses, not the seriousness of the conduct.

For holders, recoveries should be assumed to be nil. For analysts of European micro-caps, Pharmasimple is a textbook case of the risks of founder-dominated issuers on growth markets, opaque debt reporting, and death-spiral convertible financing. Rating: not rated / equity value nil.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground

Michael (Michaël) Willems

Co-founder; Chairman & CEO (PDG); director in his own name and permanent representative of AM Consultancy SRL, which held the delegated day-to-day management mandate

2010 – bankruptcy (2023)

Master's degree in biotechnology and management (FSMA decision)

Annabelle Willems

Co-founder

From 2010; later role not publicly disclosed

—

Julien Mazerolle

CEO of Enova Santé since 2017; took a new group function after the 2019 acquisition

2019 – not publicly disclosed

Ran 1001Pharmacies.com

CFO (name not disclosed)

Directeur financier; FSMA contacted the CFO in August 2019 about undeclared managers' transactions

——

SRIW representatives

Directors representing Walloon regional investor SRIW (via subsidiary Samanda SA); several successive permanent representatives

2010s – not publicly disclosed

—

Independent director nominated by Alpha Blue Ocean

Willems stated in a 2025–2026 interview that ABO wanted to appoint an independent director from January 2023, naming Jean Paul Michielsen

2,023—

“—” = not publicly disclosed.

Major Shareholders

HolderStakeDateSource

Michael Willems + AM Consultancy, Junior Invest, Acacia

10.90% before; 31.60% after the Dec 2019 capital increase

4 Dec 2019

FSMA decision

SRIW (via Samanda SA)

Significant shareholder; exact % not publicly disclosed

2019

FSMA decision

IMBC (Invest Mons-Borinage-Centre)

Public shareholder; % not publicly disclosed

2019

FSMA decision

News Invest, Sopromec Participations

Early investors (2016); % not publicly disclosed

2016

FrenchWeb; Preqin

Atout Capital

Listed by Preqin as an investor; % not publicly disclosed

—

Preqin

Four small-cap investment funds

Subscribed around the Sept 2017 Euronext Growth transfer; names not captured

2017

Release 18 Aug 2017

Global Tech Opportunities 12 (Alpha Blue Ocean)

Holder of convertible bonds/warrants and loans; resulting equity stake not publicly disclosed; largest creditor (EUR 29.8M claim)

2021–2023

Releases; Business Wire

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning relative to Pharmasimple

1001Pharmacies.com

French online parapharmacy

Named rival in 2016; acquired by Pharmasimple in 2019

Easyparapharmacie

French online parapharmacy

Named rival in 2016–2017; strong price positioning

E.Leclerc (parapharmacy)

French mass-retail parapharmacy, online and offline

Named rival in 2016; vast store network and purchasing scale

Redcare Pharmacy (formerly Shop Apotheke) / Newpharma

Belgian and European online pharmacy

Pan-European scale player with Belgian presence

DocMorris

European online pharmacy

Scale player (primarily Germany)

Cocooncenter

French online parapharmacy

Specialist e-tailer

Pharmacie Lafayette

French pharmacy chain/network with online arm

Price-led omnichannel network

Atida (Santé Discount)

French online parapharmacy

Specialist e-tailer

Multipharma

Belgian cooperative pharmacy chain

Direct competitor to the 2022 pharmacy network

Benu (Phoenix group)

Belgian pharmacy chain

Scale chain backed by a wholesaler

Médi-Market

Belgian parapharmacy chain

Discount parapharmacy stores

ComptoirSanté

French online parapharmacy

Cited in 2016 as having ceased operating — illustrates sector attrition

Peer Comparison FY2021

MetricPharmasimple (FY2020)Pharmasimple (FY2021)

Revenue (EUR Mn)

45.230.0

Revenue growth (%)

60.8-33.6

EBITDA margin (%)

2.2-15.3

Recent Developments

The company has produced no operating news since its bankruptcy.

Company Snapshot

$35.5M

Revenue

10

Employees

$0.1M

Market Cap

2010

Founded

Houdeng-Goegnies, Belgium

Headquarters

SWOT Analysis

Strengths

  • SEO-led traffic engine: site visits rose from 16.8M (2019) to 23.5M (2020) (FY2020 results).
  • Demonstrated ability to scale revenue: EUR 6.8M (2015) to EUR 45.2M (2020).
  • Acquisition integration: absorbed Parapharmazen (2018) and 1001Pharmacies (2019) and claimed number-one French organic-traffic position (Nov 2018 release).
  • Broad catalogue: 120,000 references, 770 brands, 300,000+ customers (Euronext profile, 2017).
  • Brief operating profitability: EBITDA EUR 1.0M in FY2020 and EUR 1.4M in H1 2020.
  • Supportive public shareholders: SRIW and IMBC participated in financing; SRIW provided a bridge loan in 2019 (FSMA decision).

Weaknesses

  • Thin gross margin: 14.5% (H1 2020) falling to 10.8% (H1 2021).
  • Persistent losses: negative net margins every year 2017–2021 per aggregator data; FY2021 net loss EUR 8.9M (statutory).
  • Chronic liquidity stress: supplier arrears and failed investor search in 2019 (FSMA decision).
  • High leverage: debt/equity 3.4x and solvency 22.8% at FY2021 (Signumi).
  • Governance failures: 1,737 undeclared or misdeclared managers' transactions in 2018–2019 and sanctioned insider dealing and manipulation (FSMA, Dec 2025).
  • Opaque disclosure: no audited FY2022 accounts; company net-debt figures (EUR 0.8–1.0M) irreconcilable with a EUR 29.8M creditor claim.

Opportunities

  • Belgian pharmacy consolidation — management targeted 150–200 pharmacies (May 2022).
  • Higher margins from pharmacy advice and OTC — gross margin reached ~20% in H1 2022.
  • Omnichannel synergies between online procurement and offline outlets (Mar 2022 release).
  • French online parapharmacy growth from a EUR 4.3bn base (Xerfi, 2015).
  • Own-brand development announced in 2016.
  • Real-estate ownership of pharmacy premises via Pharmasimple Immo (Jul 2022).

Threats

  • Funding withdrawal: GTO 12 ceased funding in May 2023, triggering insolvency.
  • Demand normalisation: H1 2021 revenue –47%.
  • Laboratory dependence: 2018 revenue fell 11.6% after a distribution contract was not renewed.
  • Regulation of online medicine sales: 1001Pharmacies was barred from medicine delivery (Paris Court of Appeal, Mar 2016).
  • Dilutive convertible financing: the company itself warned investors about OCABSA dilution from April 2022.
  • Regulatory and legal exposure: FSMA sanctions (2025) and a criminal complaint (2024).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 Dec 2021Strategic overhaul announcedStart of pharmacy pivot
23 Feb 2022FY2021 revenue EUR 30.0M (–34%)Confirms post-COVID reset
3 Mar 2022Bank debt cleared; 5-pharmacy deal in exclusivityPivot funded by GTO 12
23 Mar 20227 pharmacies acquired/signedFirst offline assets
16 May 20227 pharmacies integrated; 8th signed—
31 May 20224 more signed; 150–200 pharmacy ambitionAggressive target
21 Jul 20222 more pharmacies; Pharmasimple Immo createdReal-estate strategy
27 Jul 2022H1 2022 revenue EUR 14.7M; e-commerce –32%Online decline accelerates
Sep 2022Solvency rumours; company denies insolvencyEarly warning
11 Oct 2022H1 2022 results: EBITDA –3.6M, operating loss –6.0MLosses double
6 Dec 2022Reverse split relaunched after a court order was retracted; online platform sale announcedRetail holders under 50,000 shares squeezed out
12 Dec 2022Consolidation effectiveLikely origin of ISIN BE0974429624
3 Jan 2023Online platforms sold; >50 of 65 staff gone; 4 pharmacies deferred; 2023 revenue ~EUR 6MCompany shrinks to pharmacy rump
27 Jan 2023EUR 5.64M GTO 12 loanLast financing
9 Feb 2023Restructuring update: end-2022 net debt EUR 0.8M, payables EUR 2.8M, equity EUR 3.8MDebt figures later contradicted by GTO 12 claim
7 Mar 2023Update: equity EUR 2.0M after pharmacy returnsErosion of equity
15 Mar 2023Share price spikes (+82% to EUR 0.275 on the new line, per Zonebourse)Speculative trading
11 Apr 2023Update: net debt EUR 1.0M, payables EUR 2.0M, equity EUR 1.9MFinal financial disclosure
16 May 2023Admission of insolvency; trading suspendedEffective end of equity value
17 May 2023Press release: strategic financial partner stopped contractual fundingCause attributed to GTO 12
23 May 2023Court defers ruling to 5 June—
19 Jun 2023Bankruptcy declaredLiquidation begins
28 Jun 2023FSMA extends investigation to Willems-linked companiesRegulatory escalation
7–19 Jul 2023GTO 12 appeals, discloses EUR 29.8M claim and creditor plan with 68.51% supportCreditor seeks to revive company under new management
2 Aug 2023Introductory hearing at Mons Court of Appeal—
Dec 2023Mons Court of Appeal confirms bankruptcyFinal
28 Dec 2023FSMA auditor's provisional report sent to parties—
24 May 2024FSMA final investigation report—
Jul 2024Investigating judges recuse; prosecutor seeks dismissal of criminal complaint (La Libre)Criminal track stalls
24 Sep 2024FSMA management committee refers case to Sanctions Committee—
15 Sep 2025FSMA Sanctions Committee hearing—
23 Dec 2025FSMA fines Willems EUR 65k and related companies EUR 27k (total EUR 92k); named publication for 12 monthsRegulatory closure of 2018–2019 market-abuse case
2025–2026Willems gives an extended interview to La Bourse et la Vie TV blaming the financing structure for the failureContested narrative

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment (H1 2021–H1 2022): Total revenue (July 2022 revenue release) fell from EUR 15.9 Mn in H1 2021 to EUR 14.7 Mn in H1 2022.
Pharmasimple SA — Revenue by Segment (H1 2021–H1 2022)
Series (EUR Mn)H1 2021H1 2022
Total revenue (July 2022 revenue release)15.914.7
E-commerce revenue15.910.8
Pharmacies (offline) revenue03.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Euronext IPO showcase and bell-ceremony profile (ISIN BE0974302342, IPO date 14 Sep 2017) · euronext.com
  2. FSMA Sanctions Committee decision, 23 Dec 2025 (fsma.be)
  3. FSMA information note on share offer, 18 Nov 2019 (fsma.be)
  4. Company press releases (AMF/DILA open-data archive): FY2018 results · FY2019 revenue · FY2020 revenue · FY2020 results · H1 2021 revenue · GTO 12 agreement · H1 2021 results · FY2021 revenue · transformation plan · 7 pharmacies · integration · 4 pharmacies · Jul 2022 structure · H1 2022 revenue · H1 2022 results · restructuring · ABO loan · Feb 2023 update · Mar 2023 update · Apr 2023 update · insolvency · deferral · 1001Pharmacies · shareholder loans · Euronext Growth admission · Alternext transfer plan
  5. Reverse split release, 6 Dec 2022 (live.euronext.com)
  6. Business Wire (GTO 12 appeal), 19 Jul 2023 · businesswire.com
  7. BFM Bourse / TradingSat, 17 May 2023 (tradingsat.com)
  8. Cercle Finance via TradingSat, 8 Oct 2021 (tradingsat.com)
  9. Combourse / La Libre (appeal confirmation; criminal file) · combourse.com
  10. La Bourse et la Vie TV interview (labourseetlavie.com)
  11. Zonebourse (ISIN BE0974429624; 2023 performance) (zonebourse.com)
  12. Signumi registry summary (FY2021 statutory accounts) (signumi.com)
  13. Rendementbourse (aggregator margins) (rendementbourse.com)
  14. FrenchWeb (2016 funding and listing) · frenchweb.fr
  15. Preqin profile (preqin.com)
  16. Le Quotidien du Pharmacien (CNOP v. Enova Santé) (lequotidiendupharmacien.fr)
  17. Simply Wall St, Craft.co, LeadIQ (supplementary, low-reliability vendor data)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.